Shopping Cart
Remove All
Your shopping cart is currently empty
Ociperlimab
(Synonyms: WCD-118, WCD118, BGB-A1217, BGBA1217) Copy Product Info
🥰Excellent
Synonyms: WCD-118, WCD118, BGB-A1217, BGBA1217
Catalog No. T78324 Copy Product Info
🥰Excellent
Ociperlimab (BGB-A1217) is a novel humanized monoclonal antibody targeting TIGIT that exhibits antitumor activity. Ociperlimab blocks the TIGIT/PVR signaling pathway with high affinity and, through its Fc effector functions, synergistically enhances antitumor immune responses via multiple mechanisms. Ociperlimab is indicated for the treatment of advanced solid tumors.
Cas No. 2342597-93-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $182 | - | In Stock | |
| 5 mg | $593 | - | In Stock | |
| 10 mg | $943 | - | In Stock | |
| 25 mg | $1,410 | - | In Stock | |
| 50 mg | Preferential | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:99.17% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ociperlimab (BGB-A1217) is a novel humanized monoclonal antibody targeting TIGIT that exhibits antitumor activity. Ociperlimab blocks the TIGIT/PVR signaling pathway with high affinity and, through its Fc effector functions, synergistically enhances antitumor immune responses via multiple mechanisms. Ociperlimab is indicated for the treatment of advanced solid tumors. |
| Targets & IC50 | TIGIT:0.135 nM (Kd) |
| In vitro | Treatment with Ociperlimab (0-10 μg/mL) increased the secretion of IFN-γ by cytomegalovirus-specific T cells. Ociperlimab (1-1000 ng/mL) activates natural killer cells and monocytes in an FC-dependent manner. Ociperlimab removes TIGIT from the surface of T cells through FC-dependent endocytosis in vitro. [1] |
| In vivo | Ociperlimab (3 and 10 mg/kg; Intrabitoneal injection) in CT26 WT tumor-bearing human TIGIT knockout mice and MC38 tumor-bearing human TIGIT knockout mice showed that Ociperlimab produced anti-tumor effects in an FC-dependent manner. [1] |
| Synonyms | WCD-118, WCD118, BGB-A1217, BGBA1217 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TIGIT/VSIG9/VSTM3 |
| Molecular Weight | 145.12 kDa |
| Cas No. | 2342597-93-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Keywords
Preview
Related Tags: Ociperlimab chemical structure | Ociperlimab in vivo | Ociperlimab in vitro | Ociperlimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.